Business
Allarity is a clinical-stage precision medicine company focused on anti-cancer therapeutics and its Drug Response Predictor platform.
Allarity narrowed its net loss to $11.2M and free cash flow improved, but it remains pre-revenue.
The read at a glance✓ Audited against SEC data
- Business mix — Precision oncology with DRP platformWatch
- Revenue — No FY2025 revenue in local rowsWatch
- Cash — Free cash flow improved to -$14.8MNote
- Profitability — Net loss narrowed to $11.2MNote
- Balance sheet — Equity fell 16.8%Watch
- Insiders — 0 buys / 0 sellsNote
- Accounting — No forensic screen in bundleNote
Where the revenue comes from
Fiscal 2025, as Allarity Therapeutics, Inc. reports it. History and quarterly detail are in the app.
- License$320K
Leadership changes
From Allarity Therapeutics, Inc.'s own filings, the day they're filed.
- Jeffrey S. Ervin · CFO · appointmenteff. 2025-07-01
- Alexander Epshinsky · Chief Financial Officer · departureeff. 2025-06-30
- Joseph W. Vazzano · director · departureeff. 2025-06-30
Latest filings
- 10-Q · Quarterly report2026-08-14
- 8-K · Company announcement2026-08-14
- 8-K · Company announcement2026-07-01
- 8-K · Company announcement2026-06-22
- 8-K · Company announcement2026-06-02
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Allarity Therapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.